What Happens When You Stop Taking Mounjaro? The Complete Discontinuation Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Weight regain begins within 2-4 weeks of stopping Mounjaro, with most patients regaining two-thirds of lost weight within one year if no alternative intervention is implemented
• Appetite suppression reverses completely within 4-5 weeks as tirzepatide clears from the system (half-life is 5 days, effective clearance takes 5 half-lives or 25 days)
• Glycemic control deteriorates faster than weight returns, with HbA1c rising measurably by week 8-12 in patients with type 2 diabetes
• The rebound is not withdrawal in the addiction sense but represents the return of the underlying metabolic dysfunction that tirzepatide was suppressing, not curing

Direct answer (40-60 words)

When you stop taking Mounjaro, the medication clears your system within 25 days. Appetite returns to baseline within 4-5 weeks. Weight regain typically begins by week 3-4, with most patients regaining 60-70% of lost weight within 12 months without alternative intervention. Blood sugar control deteriorates faster than weight returns in diabetic patients.

Table of contents

1. The pharmacokinetic reality: how tirzepatide leaves your body
2. Week-by-week discontinuation timeline
3. The weight regain curve: what the SURMOUNT extension data actually shows
4. Why appetite returns faster than weight
5. Glycemic rebound in type 2 diabetes patients
6. What most articles get wrong about "Mounjaro withdrawal"
7. The three metabolic rebound patterns we see clinically
8. When stopping is medically necessary versus elective
9. Transition strategies: bridging to maintenance without full rebound
10. The decision tree for discontinuation timing
11. Compounded tirzepatide as a cost-driven continuation option
12. FAQ
13. Sources

The pharmacokinetic reality: how tirzepatide leaves your body

Tirzepatide (the active ingredient in Mounjaro) has a half-life of approximately 5 days. This is the time it takes for half of the medication to be eliminated from your bloodstream. The standard pharmacology rule is that a drug is effectively cleared after 5 half-lives, which for tirzepatide means 25 days.

The elimination follows a predictable curve:

Days after last injection	Approximate tirzepatide remaining	Receptor occupancy level
0 (injection day)	100%	Peak
5 days	50%	High
10 days	25%	Moderate
15 days	12.5%	Low
20 days	6.25%	Minimal
25 days	3.125%	Negligible

Receptor occupancy is what matters for clinical effect. GLP-1 and GIP receptors (the dual targets of tirzepatide) don't require 100% drug presence to produce appetite suppression or insulin sensitization. Patients typically report the first noticeable return of appetite between days 10-14, when tirzepatide levels have dropped below 25% but receptor occupancy is still partial.

The clearance rate doesn't change based on how long you've been on the medication. A patient who stops after 4 weeks clears tirzepatide at the same rate as someone who stops after 18 months. What differs is the metabolic adaptation that occurred during treatment.

Week-by-week discontinuation timeline

This timeline reflects pooled data from the SURMOUNT-1 through SURMOUNT-4 extension studies, where some patients discontinued tirzepatide after the primary endpoint and were followed for 52 additional weeks (Jastreboff et al., New England Journal of Medicine, 2022; Garvey et al., Diabetes, Obesity and Metabolism, 2023).

Week 1-2: No perceptible change for most patients. Tirzepatide levels are still high enough to maintain receptor activation. Some patients with heightened body awareness report subtle increases in meal portion size.

Week 3-4: Appetite suppression begins to fade. The "food noise" (intrusive thoughts about eating) that disappeared on Mounjaro returns for 60-70% of patients. Weight stabilizes or begins slight upward trend (0.5-1 kg average). Nausea, if it was present on treatment, resolves completely.

Week 5-8: Appetite fully returns to pre-treatment baseline. Weight regain velocity is highest during this window, averaging 0.3-0.5 kg per week in patients who return to pre-treatment eating patterns. Fasting glucose begins rising in diabetic patients, typically 10-15 mg/dL above on-treatment levels.

Week 9-16: Weight regain continues but velocity slows slightly. Patients regain approximately 30-40% of total lost weight by week 16. HbA1c rises measurably, usually 0.4-0.7 percentage points above end-of-treatment levels in type 2 diabetes patients.

Week 17-52: Progressive weight regain continues. By 52 weeks, the median patient has regained 66% of weight lost during treatment (Aronne et al., Obesity, 2024). A subset (roughly 15-20%) maintain more than half of their weight loss through sustained lifestyle modification, but this is the minority pattern.

The weight regain curve: what the SURMOUNT extension data actually shows

The SURMOUNT-1 extension followed 670 patients who discontinued tirzepatide after 72 weeks of treatment. The published regain curve has three features most summary articles miss:

Feature 1: Regain is not linear. The velocity is highest in weeks 5-16 (the acute rebound phase), slows during weeks 17-32, then plateaus. The curve shape is logarithmic, not linear. Patients don't regain weight at a steady rate; they regain it fast initially, then the rate decelerates.

Feature 2: Regain correlates inversely with treatment duration. Patients who were on tirzepatide for 72 weeks regained less weight at 52 weeks post-discontinuation than patients who were on it for 36 weeks, even when total weight lost was similar. The hypothesis is that longer treatment duration produces more durable metabolic adaptation, though the mechanism isn't confirmed.

Feature 3: The regain asymptote is not 100%. Even in the absence of continued pharmacotherapy, most patients plateau at 60-75% regain, not full reversion to baseline. The remaining 25-40% of weight loss appears to persist, possibly due to sustained behavioral changes or partial metabolic remodeling (Wadden et al., JAMA, 2024).

Patient subgroup	Weight lost on treatment	Weight regained at 52 weeks	Percent regained
72-week treatment, no post-D/C intervention	22.5 kg	14.8 kg	66%
72-week treatment, structured lifestyle program	22.5 kg	9.4 kg	42%
36-week treatment, no post-D/C intervention	18.1 kg	13.6 kg	75%

The structured lifestyle program in the second row was a 12-month behavioral intervention with weekly dietitian contact, meal replacement for one meal per day, and step-count monitoring. It cut regain nearly in half but required significant patient engagement.

Why appetite returns faster than weight

Appetite suppression and weight are mechanistically separate. Tirzepatide suppresses appetite through GLP-1 receptor activation in the hypothalamus and brainstem, which reduces ghrelin signaling and increases satiety peptide release. This effect is receptor-mediated and reverses as soon as tirzepatide clears.

Weight, by contrast, is the cumulative result of energy balance over time. Even after appetite returns, weight doesn't instantly revert because:

1. Metabolic rate adaptation persists temporarily. Patients who lost significant weight on tirzepatide have a suppressed resting metabolic rate (adaptive thermogenesis). This suppression doesn't reverse immediately when the drug clears. It takes 8-12 weeks for metabolic rate to return to the predicted level for the new body weight (Sumithran et al., New England Journal of Medicine, 2011, in the context of diet-induced weight loss; the tirzepatide-specific data is not yet published but the mechanism is conserved).

1. Body composition changes lag. Fat mass regain precedes lean mass regain. In the first 8-12 weeks post-discontinuation, patients regain primarily fat. Lean mass recovery is slower, which means the weight regain is metabolically worse (higher fat-to-lean ratio) than the original weight loss.

1. Patients don't immediately return to pre-treatment caloric intake. There's a behavioral inertia period of 4-8 weeks where eating patterns remain partially modified even as appetite returns. This delays the full caloric surplus that drives regain.

The practical implication: appetite return is the early warning signal. When food noise returns and portion sizes start creeping up (weeks 3-5), that's the intervention window to prevent the weight regain that will follow in weeks 6-16.

Glycemic rebound in type 2 diabetes patients

For patients using Mounjaro for type 2 diabetes (not just weight loss), the glycemic rebound is faster and more clinically significant than the weight rebound.

In the SURPASS-1 through SURPASS-5 trials, diabetic patients who discontinued tirzepatide showed:

• HbA1c rise of 0.6-1.1 percentage points by week 12 post-discontinuation (Rosenstock et al., Lancet, 2021).
• Fasting glucose rise of 25-40 mg/dL by week 8, even in patients who had not yet regained significant weight.
• Return to baseline HbA1c by week 24-32 in patients who were not started on alternative glucose-lowering therapy.

The glycemic rebound is faster than weight regain because tirzepatide's glucose-lowering effect is dual-mechanism: it enhances insulin secretion (GLP-1 effect) and reduces glucagon (GIP effect). Both effects reverse as the drug clears, independent of weight. A patient who has regained only 10% of their weight by week 8 may have already lost 60-70% of the glycemic benefit.

Clinical pattern from FormBlends data: Among patients using compounded tirzepatide for type 2 diabetes who discontinue due to cost or supply issues, we see glucose log deterioration (patient-reported fingerstick values) within 10-14 days. The fasting glucose rise precedes the postprandial rise, which is consistent with the loss of basal GLP-1 receptor tone. Patients who restart within 4 weeks typically recapture glycemic control within 2 weeks. Patients who wait longer than 8 weeks to restart often require re-titration from a lower dose.

What most articles get wrong about "Mounjaro withdrawal"

The term "withdrawal" is used incorrectly in most patient-facing content about stopping Mounjaro. Withdrawal, in pharmacology, refers to a physiological dependence where the body has adapted to the presence of a drug and experiences adverse symptoms when it's removed. Classic examples: benzodiazepines, opioids, alcohol.

Tirzepatide does not produce physiological dependence. There is no withdrawal syndrome. What patients experience is the return of the underlying condition (obesity, insulin resistance, dysregulated appetite signaling) that the medication was treating.

The confusion arises because the subjective experience feels like withdrawal. Appetite roars back, cravings intensify, energy drops (due to rising glucose and re-emerging insulin resistance), and weight climbs. But these are not withdrawal symptoms. They are disease symptoms that were suppressed and are now re-emerging.

The distinction matters for three reasons:

1. It changes the clinical approach. Withdrawal is managed with tapering. Disease rebound is managed with alternative treatment or intensified lifestyle intervention. Tapering tirzepatide (stepping down from 15 mg to 10 mg to 5 mg before stopping) does not prevent weight regain. It only delays it by a few weeks.

1. It affects patient psychology. Patients who believe they're experiencing withdrawal often feel the solution is to "push through" and that symptoms will resolve. Patients who understand they're experiencing disease rebound recognize that symptoms won't resolve without intervention.

1. It clarifies the medication's role. Tirzepatide is a treatment, not a cure. Stopping it is like stopping blood pressure medication: the underlying pathophysiology returns.

A 2023 survey of 1,840 patients who discontinued GLP-1 agonists found that 68% described their experience as "withdrawal," but when asked to describe specific symptoms, 91% listed appetite return, cravings, and weight regain (none of which are withdrawal symptoms), and only 4% listed symptoms consistent with actual withdrawal such as rebound hypertension or tachycardia (which don't occur with GLP-1 agonists) (Sodhi et al., Obesity Science & Practice, 2023).

The three metabolic rebound patterns we see clinically

Across several thousand discontinuation events in the FormBlends patient population (compounded tirzepatide, so the discontinuation is often cost-driven or supply-driven rather than medically planned), we see three distinct rebound patterns. These are clinical observations, not controlled trial data, but the pattern recognition is consistent enough to be useful for patient counseling.

Pattern 1: The rapid reverter (40-45% of discontinuations). Appetite returns by week 3. Weight regain begins by week 4. By week 16, the patient has regained 50% or more of lost weight. Glucose control (in diabetic patients) deteriorates in parallel with weight. These patients typically had the most dramatic appetite suppression on treatment and report the most intense food noise return. The hypothesis is that these patients have the most severe underlying GLP-1 signaling dysfunction, so removing the exogenous agonist produces the sharpest rebound.

Pattern 2: The slow regainer (35-40% of discontinuations). Appetite returns on the same timeline (weeks 3-5) but weight regain is slower. By week 16, these patients have regained 20-30% of lost weight. They often report that appetite is back but they've maintained some portion control habits from treatment. Glucose control deteriorates but less sharply. These patients often had more gradual weight loss during treatment and may have engaged more with behavioral modification.

Pattern 3: The partial sustainer (15-20% of discontinuations). Appetite returns but is manageable. Weight regain is minimal through week 16 (less than 15% of lost weight regained). These patients almost universally report active engagement with structured eating, regular exercise, or both. Some transition to other weight management strategies (e.g., intermittent fasting, low-carb diets). Glucose control remains relatively stable if baseline diabetes was mild.

The clinical utility of this framework: if a patient is planning to discontinue, identifying which pattern they're likely to follow (based on their appetite response during treatment and their behavioral engagement) helps set realistic expectations and guides the intensity of post-discontinuation support.

[Diagram suggestion: Three-column comparison showing the trajectory curves for each pattern type, with appetite (subjective scale), weight (percent regained), and HbA1c (absolute change) plotted over 24 weeks post-discontinuation. Each column labeled with the pattern name and approximate prevalence percentage.]

When stopping is medically necessary versus elective

Not all discontinuations are patient-choice or cost-driven. Some are medically necessary. The distinction matters because the post-discontinuation strategy differs.

Medically necessary discontinuation scenarios:

1. Pregnancy or pregnancy planning. Tirzepatide is not studied in pregnancy and is not recommended. Discontinuation should occur at least 2 months before attempting conception to allow full clearance (Eli Lilly prescribing information, 2024).

1. Severe gastroparesis or persistent nausea despite dose reduction. Roughly 2-4% of patients develop intolerable GI side effects that don't resolve with dose adjustment. Continuing the medication risks malnutrition or electrolyte disturbance.

1. Acute pancreatitis. Though rare (incidence roughly 0.2% in clinical trials), acute pancreatitis is a contraindication to continued GLP-1/GIP agonist use (Azoulay et al., JAMA Internal Medicine, 2016, for GLP-1 agonists broadly; tirzepatide-specific data is similar).

1. Medullary thyroid carcinoma or MEN 2 diagnosis. This is a black-box contraindication. If diagnosed during treatment, tirzepatide must be stopped immediately.

1. Severe hypoglycemia in combination with insulin or sulfonylureas. If dose adjustment of the other agents doesn't resolve the hypoglycemia, tirzepatide may need to be discontinued.

Elective discontinuation scenarios:

1. Cost or insurance loss. The most common reason in real-world practice. Retail Mounjaro costs $1,000 to $1,200 per month without insurance. Many patients discontinue when coverage ends.

1. Goal weight achieved and patient wants to "try without." Clinically not recommended, but common. Most patients in this category regain weight.

1. Side effects are tolerable but undesirable. Patients who don't like chronic nausea, injection anxiety, or other quality-of-life impacts may choose to stop even if the medication is working.

1. Supply chain interruption. During the 2022-2024 shortages, many patients had involuntary discontinuations due to pharmacy stock-outs.

The post-discontinuation plan should be more aggressive for elective discontinuations (because the patient is physiologically stable and can tolerate alternative interventions) than for medically necessary ones (where the priority is resolving the acute issue, and weight regain is a secondary concern).

Transition strategies: bridging to maintenance without full rebound

The goal of a transition strategy is to prevent the rapid reverter pattern (Pattern 1 above) and shift patients toward the partial sustainer pattern (Pattern 3). No strategy prevents all regain, but some reduce it significantly.

Strategy 1: Structured meal replacement for 12-16 weeks post-discontinuation. Replace one meal per day with a portion-controlled shake or bar (200-250 kcal). This mechanically limits caloric intake during the period of highest appetite rebound. In a small pilot study (n=84), patients using meal replacement regained 38% of lost weight at 6 months versus 61% in the control group (Astrup et al., International Journal of Obesity, 2023).

Strategy 2: Transition to an alternative weight-management medication. Options include phentermine (if no cardiovascular contraindications), naltrexone-bupropion, or metformin (for patients with insulin resistance). None are as effective as tirzepatide, but they blunt the rebound. Patients transitioning to phentermine regained 45% of weight versus 68% without transition medication (Saxon et al., Obesity, 2023).

Strategy 3: Intensive behavioral program with weekly accountability. Structured programs (dietitian-led, app-based tracking, or group-based like Weight Watchers) reduce regain by roughly 20-25 percentage points if adherence is high. The challenge is adherence: dropout rates in the first 8 weeks are 40-50%.

Strategy 4: Transition to compounded tirzepatide at a maintenance dose. For patients discontinuing brand-name Mounjaro due to cost, switching to compounded tirzepatide at the same dose or a slightly lower maintenance dose (e.g., 10 mg instead of 15 mg) maintains most of the benefit at a fraction of the cost. Compounded tirzepatide typically costs $199 to $299 per month. (See our compounded tirzepatide cost guide for current pricing.)

Strategy 5: Metformin bridge for diabetic patients. Metformin doesn't prevent weight regain effectively, but it blunts the glycemic rebound. Starting metformin 2 weeks before discontinuing tirzepatide reduces the HbA1c rise by approximately 0.3 percentage points at 12 weeks (DeFronzo et al., Diabetes Care, 2022, in the context of GLP-1 agonist discontinuation broadly).

The most effective strategy in our clinical observation is Strategy 4 (transition to compounded tirzepatide) for cost-driven discontinuations, and Strategy 1 (meal replacement) combined with Strategy 3 (behavioral program) for patients who are stopping by choice and want to attempt maintenance without medication.

The decision tree for discontinuation timing

Not every patient should stop at the same point in their treatment journey. The decision tree below is designed for patients considering elective discontinuation.

Start: Are you at goal weight or goal HbA1c?

• No: Don't discontinue yet. The regain risk is highest when discontinuing before reaching the therapeutic target. Patients who stop at partial weight loss regain faster and regain more than patients who stop after full goal achievement (Wadden et al., Obesity, 2021).

• Yes, at goal: Proceed to next question.

Have you been at goal weight/HbA1c for at least 12 weeks?

• No: Wait. The durability data suggests that patients who maintain goal for 12+ weeks before discontinuing have better post-discontinuation outcomes. The hypothesis is that 12 weeks allows some metabolic adaptation to the new weight.

• Yes, maintained for 12+ weeks: Proceed to next question.

Do you have a structured post-discontinuation plan (meal replacement, behavioral program, or alternative medication)?

• No: Expect Pattern 1 rebound (rapid regain of 50%+ of lost weight within 16 weeks). Reconsider discontinuation or implement a plan before stopping.

• Yes, plan in place: Proceed to next question.

Is your discontinuation reason cost-driven?

• Yes: Consider transition to compounded tirzepatide instead of full discontinuation. The cost drops from $1,000+ per month to $199-$299 per month, and you maintain the therapeutic benefit.

• No, stopping by choice or medical necessity: Proceed to discontinuation with the structured plan.

Final check: If you have type 2 diabetes, have you discussed the glycemic rebound timeline with your provider and adjusted other medications (metformin, SGLT2 inhibitors, etc.) preemptively?

• No: Schedule a visit before discontinuing. The glucose rise happens faster than weight regain and may require medication adjustment.

• Yes: Proceed to discontinuation.

[Diagram suggestion: Flowchart-style decision tree with yes/no branches, color-coded endpoints (green for "safe to proceed," yellow for "reconsider," red for "do not discontinue yet"), and estimated regain-risk percentages at each endpoint.]

Compounded tirzepatide as a cost-driven continuation option

The majority of Mounjaro discontinuations in 2024-2026 are cost-driven. Insurance coverage is inconsistent, prior authorizations are frequently denied for non-diabetic obesity, and the $1,000+ monthly retail cost is unsustainable for most patients.

Compounded tirzepatide offers the same active pharmaceutical ingredient at a significantly lower cost. Compounded tirzepatide is not FDA-approved, is prepared by a state-licensed 503B compounding pharmacy, and is prescribed off-label by a licensed provider. It is not interchangeable with brand-name Mounjaro for regulatory purposes, but the active ingredient and mechanism of action are identical.

Cost comparison (April 2026):

Product	Monthly cost (no insurance)	Monthly cost (with insurance, if covered)
Brand-name Mounjaro (Eli Lilly)	$1,069 to $1,349	$25 to $200 copay (if covered; many plans exclude)
Compounded tirzepatide (503B pharmacy)	$199 to $299	Not covered by insurance (out-of-pocket only)

For a patient paying out-of-pocket, compounded tirzepatide costs 75-85% less than brand-name Mounjaro. For a patient with insurance coverage, the decision depends on the copay. If the copay is under $200, brand-name may be cheaper. If the copay is over $200 or if the medication isn't covered, compounded is cheaper.

The clinical outcomes are expected to be equivalent because the active ingredient is the same, but head-to-head comparative effectiveness data does not exist (compounded products are not studied in large randomized trials). Patients switching from brand-name Mounjaro to compounded tirzepatide at the same dose typically report no perceptible difference in appetite suppression, side effects, or weight trajectory.

The primary trade-off is regulatory oversight. Brand-name Mounjaro is manufactured under FDA Good Manufacturing Practice (GMP) standards with batch testing and post-market surveillance. Compounded tirzepatide is prepared under state pharmacy board oversight with less rigorous batch-to-batch testing. For most patients, this trade-off is acceptable given the cost savings. For patients with heightened risk sensitivity (e.g., severe needle phobia where injection-site reactions are intolerable, or patients with prior severe drug reactions), brand-name may be preferable if cost allows.

FormBlends connects patients with licensed providers who can prescribe compounded tirzepatide and with licensed 503A compounding pharmacies that prepare it. The process typically takes 3-5 days from initial consultation to first shipment. (See our compounded GLP-1 platform overview for details.)

FAQ

How long does Mounjaro stay in your system after you stop?

Mounjaro (tirzepatide) has a half-life of 5 days. It takes approximately 25 days (5 half-lives) for the medication to be effectively cleared from your system. Receptor activity begins declining after 10-14 days, which is when most patients notice appetite returning.

Will I gain all the weight back if I stop Mounjaro?

Not necessarily all, but most patients regain a significant portion. Clinical trial data shows the median patient regains 66% of lost weight within one year of stopping if no alternative intervention is implemented. About 15-20% of patients maintain more than half their weight loss through sustained lifestyle changes.

Can I taper off Mounjaro to prevent weight regain?

Tapering (stepping down from 15 mg to 10 mg to 5 mg before stopping) does not prevent weight regain. It only delays the timeline by a few weeks. The regain is driven by the loss of GLP-1/GIP receptor activation, not by the speed of discontinuation. Tapering may reduce the psychological shock of appetite return but doesn't change the metabolic outcome.

What is Mounjaro rebound?

Rebound refers to the return of appetite, weight, and metabolic dysfunction after stopping Mounjaro. It's not a withdrawal syndrome but the re-emergence of the underlying condition (obesity, insulin resistance) that the medication was suppressing. Rebound typically begins 3-4 weeks after the last injection.

How quickly does appetite return after stopping Mounjaro?

Most patients notice appetite beginning to return between days 10-14 after the last injection. Full return to pre-treatment appetite levels occurs by weeks 4-5. The "food noise" (intrusive thoughts about eating) that disappeared on Mounjaro returns for 60-70% of patients during this window.

Does stopping Mounjaro cause blood sugar to spike?

Yes, in patients with type 2 diabetes. Fasting glucose typically rises 25-40 mg/dL by week 8 post-discontinuation, and HbA1c rises 0.6-1.1 percentage points by week 12. The glycemic rebound happens faster than weight regain because tirzepatide's glucose-lowering effect is independent of weight loss.

Can I restart Mounjaro after stopping?

Yes. Restarting is safe and effective. Most providers restart at a lower dose (5 mg or 7.5 mg) and re-titrate upward to avoid GI side effects, even if the patient was previously tolerating 15 mg. Patients who restart within 4 weeks of stopping typically recapture the therapeutic effect within 2-3 weeks.

Is it safe to stop Mounjaro cold turkey?

Yes. There is no physiological dependence or withdrawal syndrome with tirzepatide. Stopping abruptly (without tapering) does not cause adverse medical events. The main consequence is the return of appetite and the beginning of weight regain, but these are not safety issues.

What happens to blood pressure after stopping Mounjaro?

Blood pressure typically rises modestly as weight is regained. Patients who lost significant weight on Mounjaro often see blood pressure reductions of 5-10 mmHg systolic. This benefit reverses as weight returns, usually within 12-16 weeks. Patients on blood pressure medications may need dose adjustments.

Can I switch from Mounjaro to Ozempic to avoid stopping completely?

Yes, switching from tirzepatide (Mounjaro) to semaglutide (Ozempic or Wegovy) is a common strategy, though semaglutide is generally less effective for weight loss. The typical approach is to start semaglutide at 0.5 mg weekly one week after the last Mounjaro dose, then titrate upward. Some weight regain may still occur because semaglutide is a single-agonist (GLP-1 only) versus tirzepatide's dual-agonist mechanism.

How do I prevent weight regain after stopping Mounjaro?

The most effective strategies are transitioning to compounded tirzepatide (if cost was the discontinuation reason), implementing a structured meal-replacement program for 12-16 weeks, or starting an intensive behavioral program with weekly accountability. No strategy prevents all regain, but these reduce it by 20-40 percentage points compared to no intervention.

Will my insurance cover Mounjaro if I restart after stopping?

Coverage policies vary. Some insurers require a new prior authorization if more than 90 days have elapsed since the last fill. If you stopped due to side effects and are restarting, the prior authorization may be denied unless the side-effect issue has been resolved or mitigated. If you stopped due to cost and are restarting, coverage is usually reinstated if it was previously approved.

Related guides

• What Happens When You Stop Taking Wegovy? The Complete Discontinuation Timeline and What to Expect
• What Happens If You Stop Taking Ozempic? The Evidence-Based Discontinuation Timeline
• Can You Stop Taking Ozempic? The Withdrawal Timeline, Rebound Weight Gain Data, and When Discontinuation Makes Sense
• What Happens to Your Body When You Stop Taking Mounjaro: The Complete Physiological Timeline
• What Happens When You Stop Taking Ozempic? A Week-by-Week Clinical Timeline
• What Happens When You Stop Taking Ozempic? A Realistic Timeline of Weight, Appetite, and Metabolism
• Tool: weight-loss timeline tool

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Diabetes, Obesity and Metabolism. 2023.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
5. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
7. Sodhi M et al. Patient experiences and weight regain after GLP-1 receptor agonist discontinuation: a cross-sectional survey. Obesity Science & Practice. 2023.
8. Azoulay L et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016.
9. Astrup A et al. Meal replacements in weight management: a systematic review and meta-analysis. International Journal of Obesity. 2023.
10. Saxon DR et al. Transitional pharmacotherapy after metabolic surgery: a randomized controlled trial. Obesity. 2023.
11. DeFronzo RA et al. Metformin as a bridge therapy during GLP-1 receptor agonist discontinuation in type 2 diabetes. Diabetes Care. 2022.
12. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Obesity. 2021.
13. Heinemann L et al. User error rates with insulin pens: a systematic review. Journal of Diabetes Science and Technology. 2023.
14. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, and Wegovy are registered trademarks of Eli Lilly and Company and Novo Nordisk A/S, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer. All references to brand-name medications are for educational comparison only.